ADC Therapeutics (ADCT) Competitors $1.20 -0.02 (-1.24%) Closing price 03:59 PM EasternExtended Trading$1.21 +0.01 (+1.26%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADCT vs. URGN, MGTX, IMTX, ARVN, SION, CGEM, AKBA, PRTC, SAGE, and MNMDShould you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include UroGen Pharma (URGN), MeiraGTx (MGTX), Immatics (IMTX), Arvinas (ARVN), Sionna Therapeutics (SION), Cullinan Therapeutics (CGEM), Akebia Therapeutics (AKBA), PureTech Health (PRTC), Sage Therapeutics (SAGE), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. ADC Therapeutics vs. UroGen Pharma MeiraGTx Immatics Arvinas Sionna Therapeutics Cullinan Therapeutics Akebia Therapeutics PureTech Health Sage Therapeutics Mind Medicine (MindMed) UroGen Pharma (NASDAQ:URGN) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has more risk and volatility, URGN or ADCT? UroGen Pharma has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Do analysts rate URGN or ADCT? UroGen Pharma currently has a consensus price target of $38.20, suggesting a potential upside of 255.35%. ADC Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 548.54%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than UroGen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of URGN or ADCT? 91.3% of UroGen Pharma shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 5.1% of UroGen Pharma shares are owned by insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer URGN or ADCT? In the previous week, UroGen Pharma had 6 more articles in the media than ADC Therapeutics. MarketBeat recorded 6 mentions for UroGen Pharma and 0 mentions for ADC Therapeutics. UroGen Pharma's average media sentiment score of 1.22 beat ADC Therapeutics' score of 0.00 indicating that UroGen Pharma is being referred to more favorably in the media. Company Overall Sentiment UroGen Pharma Positive ADC Therapeutics Neutral Is URGN or ADCT more profitable? UroGen Pharma has a net margin of -129.11% compared to ADC Therapeutics' net margin of -300.00%. Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% ADC Therapeutics -300.00%N/A -61.33% Which has stronger valuation and earnings, URGN or ADCT? UroGen Pharma has higher revenue and earnings than ADC Therapeutics. UroGen Pharma is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$90.40M5.48-$102.24M-$3.23-3.33ADC Therapeutics$70.84M1.67-$240.05M-$1.65-0.72 Does the MarketBeat Community favor URGN or ADCT? UroGen Pharma received 311 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 74.30% of users gave UroGen Pharma an outperform vote while only 68.89% of users gave ADC Therapeutics an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes37374.30% Underperform Votes12925.70% ADC TherapeuticsOutperform Votes6268.89% Underperform Votes2831.11% SummaryUroGen Pharma beats ADC Therapeutics on 13 of the 17 factors compared between the two stocks. Remove Ads Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADCT vs. The Competition Export to ExcelMetricADC TherapeuticsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$118.41M$6.32B$5.33B$18.52BDividend YieldN/A3.23%5.11%4.24%P/E Ratio-0.506.7921.7331.15Price / Sales1.67225.93379.1925.69Price / CashN/A65.6738.1517.53Price / Book-0.625.866.464.29Net Income-$240.05M$141.86M$3.20B$1.02B7 Day Performance8.14%8.98%6.54%6.59%1 Month Performance-35.23%-12.65%-8.55%-6.88%1 Year Performance-72.59%-11.99%10.33%1.23% ADC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADCTADC Therapeutics2.131 of 5 stars$1.20-1.2%$7.75+548.5%-72.6%$118.41M$70.84M-0.50310Gap DownURGNUroGen Pharma3.9177 of 5 stars$9.96-2.8%$38.20+283.5%-29.8%$459.10M$90.40M-3.16200MGTXMeiraGTx4.57 of 5 stars$5.75+1.2%$24.50+326.1%-1.4%$453.42M$33.28M-4.75300Gap UpHigh Trading VolumeIMTXImmatics2.357 of 5 stars$3.68+5.1%$16.67+352.9%-60.1%$439.23M$155.84M-5.58260Short Interest ↓Gap DownHigh Trading VolumeARVNArvinas3.7037 of 5 stars$6.37-2.9%$35.50+457.3%-79.6%$438.08M$263.40M-2.30420Short Interest ↓High Trading VolumeSIONSionna TherapeuticsN/A$9.73-2.4%$38.50+295.7%N/A$429.33MN/A0.0035CGEMCullinan Therapeutics2.3193 of 5 stars$7.25-2.2%$32.86+353.2%-53.6%$424.22MN/A-2.5530News CoveragePositive NewsAKBAAkebia Therapeutics3.4576 of 5 stars$1.77flat$6.50+267.2%+25.3%$418.13M$160.18M-7.70430Gap DownPRTCPureTech Health2.5934 of 5 stars$17.30flat$45.00+160.1%-38.3%$415.53M$3.33M0.00100Short Interest ↓Gap UpHigh Trading VolumeSAGESage Therapeutics3.7652 of 5 stars$6.66-2.9%$8.81+32.3%-52.1%$409.46M$41.24M-1.01690News CoverageMNMDMind Medicine (MindMed)1.9291 of 5 stars$5.43flat$25.11+362.5%-42.6%$409.25MN/A-2.4040 Remove Ads Related Companies and Tools Related Companies URGN Alternatives MGTX Alternatives IMTX Alternatives ARVN Alternatives SION Alternatives CGEM Alternatives AKBA Alternatives PRTC Alternatives SAGE Alternatives MNMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ADCT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADCT Stock Free ADCT Stock Alerts